Search Results - "Gordon, K.B"

Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory by Gordon, K.B., Kimball, A.B., Chau, D., Viswanathan, H.N., Li, J., Revicki, D.A., Kricorian, G., Ortmeier, B.G.

“…Summary Background Psoriasis symptoms have a significant negative impact on health‐related quality of life, impairing physical functioning and well‐being…”
Get full text

Human and Porcine Islet Transplants in a New Double Capsule by Safley, S.A, Gordon, K.B, Barber, G.F, Holdcraft, R.W, Turgeon, N, Larsen, C.P, Gazda, L, Weber, C.J

Get full text

Understanding Debriefing: A Qualitative Study of Event Reconstruction at an Academic Medical Center by Sweeney, Rachel E, Clapp, Justin T, Arriaga, Alexander F, Muralidharan, Madhavi, Burson, Randall C, Gordon, Emily K.B, Falk, Scott A, Baranov, Dimitry Y, Fleisher, Lee A

“…PURPOSEThis qualitative study sought to characterize the role of debriefing after real critical events among anesthesia residents at the Hospital of the…”
Get full text

Encouraging Reflexivity in a Residency Leadership Development Program: Expanding Outside the Competency Approach by Clapp, Justin T., Gordon, Emily K.B., Baranov, Dimitry Y., Trey, Beulah, Tilin, Felice J., Fleisher, Lee A.

“…PROBLEMWhile leadership development is increasingly a goal of academic medicine, it is typically framed as competency acquisition, which can limit its focus to…”
Get full text

Long‐term safety of risankizumab from 17 clinical trials in patients with moderate‐to‐severe plaque psoriasis by Gordon, K.B., Lebwohl, M., Papp, K.A., Bachelez, H., Wu, J.J., Langley, R.G., Blauvelt, A., Kaplan, B., Shah, M., Zhao, Y., Sinvhal, R., Reich, K.

“…Summary Background Risankizumab has demonstrated efficacy and safety in patients with moderate‐to‐severe plaque psoriasis in randomized clinical trials…”
Get full text

Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER‐3 study by Lebwohl, M.G., Gordon, K.B., Gallo, G., Zhang, L., Paul, C.

“…Background Psoriasis, a chronic disease usually requires long‐term disease management. Objective This study evaluates the efficacy and safety of recommended…”
Get full text

Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate‐to‐severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE‐2 and AMAGINE‐3 by Papp, K.A., Gordon, K.B., Langley, R.G., Lebwohl, M.G., Gottlieb, A.B., Rastogi, S., Pillai, R., Israel, R.J.

“…Summary Background Biologics are being used increasingly to treat moderate‐to‐severe psoriasis. Efficacy may differ in patients with previous exposure to…”
Get full text

Anxiety and depression in patients with moderate‐to‐severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study by Gordon, K.B., Armstrong, A.W., Han, C., Foley, P., Song, M., Wasfi, Y., You, Y., Shen, Y.‐K., Reich, K.

“…Background Anxiety and depression are clinically significant comorbidities associated with psoriasis. Improvements in psoriasis are known to decrease anxiety…”
Get full text

Efficacy of guselkumab in subpopulations of patients with moderate‐to‐severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies by Gordon, K.B., Blauvelt, A., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Shen, Y.K., You, Y., Griffiths, C.E.M.

“…Summary Background Significant advances have been made in the treatment of moderate‐to‐severe plaque psoriasis with biological therapies; however, these agents…”
Get full text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study by Kimball, A.B., Papp, K.A., Wasfi, Y., Chan, D., Bissonnette, R., Sofen, H., Yeilding, N., Li, S., Szapary, P., Gordon, K.B.

“…Background  Ongoing evaluation of biological agents in patients with moderate‐to‐severe psoriasis is needed to support their long‐term use. Objective  To…”
Get full text

Super‐response to guselkumab treatment in patients with moderate‐to‐severe psoriasis: age, body weight, baseline Psoriasis Area and Severity Index, and baseline Investigator's Global Assessment scores predict complete skin clearance by Reich, K., Gordon, K.B., Strober, B., Langley, R.G., Miller, M., Yang, Y.‐W., Shen, Y.‐K., You, Y., Zhu, Y., Foley, P., Blauvelt, A.

“…Background Psoriasis is a chronic immune‐mediated inflammatory skin disease that often leads to a diminished quality of life. Goals of treating patients with…”
Get full text

Long‐term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3‐year results from two randomized phase III trials (CIMPASI‐1 and CIMPASI‐2) by Gordon, K.B., Warren, R.B., Gottlieb, A.B., Blauvelt, A., Thaçi, D., Leonardi, C., Poulin, Y., Boehnlein, M., Brock, F., Ecoffet, C., Reich, K.

“…Summary Background Certolizumab pegol (CZP) is an Fc‐free, PEGylated anti‐tumour necrosis factor biologic. Objectives To report the 3‐year efficacy of CZP in…”
Get full text

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies by MENTER, Alan, KORMAN, Neil J, VAN VOORHEES, Abby S, BEUTNER, Karl R, BHUSHAN, Reva, ELMETS, Craig A, FELDMAN, Steven R, GELFAND, Joel M, GORDON, Kenneth B, GOTTLIEB, Alice, KOO, John Y. M, LEBWOHL, Mark, LIM, Henry W

“…Psoriasis is a common, chronic, inflammatory, multi-system disease with predominantly skin and joint manifestations affecting approximately 2% of the…”
Get full text

Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years by Kimball, A.B., Gordon, K.B., Fakharzadeh, S., Yeilding, N., Szapary, P.O., Schenkel, B., Guzzo, C., Li, S., Papp, K.A.

“…Summary Background  An unmet need remains for safe and effective long‐term treatments of psoriasis. Objectives  To evaluate ustekinumab efficacy and safety for…”
Get full text

Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis by Blauvelt, A., Papp, K.A., Sofen, H., Augustin, M., Yosipovitch, G., Katoh, N., Mrowietz, U., Ohtsuki, M., Poulin, Y., Shrom, D., Burge, R., See, K., Mallbris, L., Gordon, K.B.

“…Background Continuous treatment is recommended for patients with moderate‐to‐severe psoriasis; however, treatment may need to be interrupted in routine…”
Get full text

Long‐term optimization of outcomes with flexible adalimumab dosing in patients with moderate to severe plaque psoriasis by Gniadecki, R., Leonardi, C.L., Gordon, K.B., Gu, Y., Geng, Z., Nader, A., Teixeira, H.D.

“…Background The recently updated dosing recommendation for adalimumab for moderate to severe plaque psoriasis states that patients with inadequate response to…”
Get full text

Defining drug‐free remission of skin disease in patients with plaque psoriasis by Armstrong, A.W., Blauvelt, A., Crowley, J.J., Gordon, K.B., Krueger, G.G., Krueger, J.G., Sobell, J.M., Strober, B.E., Srivastava, B., Menter, A.

Get full text

Correlation of psoriasis activity with socioeconomic status: cross‐sectional analysis of patients enrolled in the Psoriasis Longitudinal Assessment and Registry (PSOLAR) by Kimball, A.B., Augustin, M., Gordon, K.B., Krueger, G.G., Pariser, D., Fakharzadeh, S., Goyal, K., Calabro, S., Lee, S., Lin, R., Li, N., Srivastava, B., Guenther, L.

Get full text

A study comparing the biologic drugs ixekizumab and guselkumab for the treatment of moderate‐to‐severe plaque psoriasis by Blauvelt, A., Papp, K., Gottlieb, A., Jarell, A., Reich, K., Maari, C., Gordon, K.B., Ferris, L.K., Langley, R.G., Tada, Y., Lima, R.G., Elmaraghy, H., Gallo, G., Renda, L., Park, S.Y., Burge, R., Bagel, J.

“…Summary Psoriasis is a skin disease that causes red, scaly and itchy patches of skin all over the body. It affects about 125 million people worldwide. As well…”
Get full text

A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab by Edson-Heredia, E., Banerjee, S., Zhu, B., Maeda-Chubachi, T., Cameron, G.S., Shen, W., Heffernan, M.P., Gordon, K.B., Leonardi, C.L.

Get full text